

1 **Per- and polyfluoroalkyl substances concentrations are associated with an unfavorable cardio-metabolic**
2 **risk profile: findings from two population-based cohort studies**

3
4 **Authors:** Tariq O. Faquih^{1*}, Elvire N. Landstra^{2*}, Astrid van Hylekama Vlieg¹, N.Ahmad Aziz^{2,3}, Ruifang Li-
5 Gao^{1,4}, Renée de Mutsert¹, Frits R. Rosendaal¹, Raymond Noordam⁵, Diana van Heemst⁵, Dennis O. Mook-
6 Kanamori^{1,6}, Ko Willems van Dijk^{7,8,9}, Monique M.B. Breteler^{2,10}

7 ¹ Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands

8 ² Population Health Sciences, German Centre for Neurodegenerative Diseases (DZNE), Bonn, Germany

9 ³ Department of Neurology, Faculty of Medicine, University of Bonn, Bonn, Germany

10 ⁴ Metabolon, Inc. Morrisville, North Carolina, United State of America

11 ⁵ Department of Internal Medicine, Section of Gerontology and Geriatrics, Leiden University Medical Center,
12 Leiden, The Netherlands

13 ⁶ Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, The Netherlands

14 ⁷ Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands

15 ⁸ Department of Internal Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, The
16 Netherlands

17 ⁹ Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The
18 Netherlands

19 ¹⁰ Institute for Medical Biometry, Informatics and Epidemiology (IMBIE), Faculty of Medicine, University of
20 Bonn, Germany

21

22 *Authors contributed equally to this project

23

24 Abstract word count: 244

25 Main manuscript word count: 3735

26 Number of tables: 2

27 Number of figures: 3

28 Number of supplementary tables: 2

29 Number of supplementary figures: 1

30

31 Keywords: PFAS exposure, general population, cohort study, metabolomics, lipoproteins, cardiovascular
32 disease risk, meta-analysis

33

34 **Corresponding author:**

35 Monique M.B. Breteler

36 Monique.Breteler@dzne.de

37 Venusberg-Campus 1, Building 99

38 53127 Bonn, Germany

39

40 **Acknowledgements**

41 We would like to thank all participants and the study personnel of the Rhineland Study. The authors of the NEO
42 study thank all participants, all participating general practitioners for inviting eligible participants, all research
43 nurses for data collection, and the NEO study group: Pat van Beelen, Petra Noordijk, and Ingeborg de Jonge for
44 study coordination, laboratory, and data management.

45

46 **Abstract**

47 Per- and polyfluoroalkyl substances (PFAS) are widely used and persistent chemicals, leading to ubiquitous
48 exposure. Although high PFAS levels have been associated with an adverse cardiovascular risk profile, the
49 distribution of levels and relations with cardio-metabolic risk markers in the general population have not been
50 fully characterized. We assessed the association between blood levels of perfluorooctaneic acid (PFOA),
51 perfluorooctane sulfonic acid (PFOS), and perfluorohexanesulfonic acid (PFHxS) and a range of lipoproteins
52 and metabolites as well as clinical lipid measurements. We used data from participants of the Netherlands
53 Epidemiology of Obesity study (NEO) (n= 584) and the Rhineland Study (n= 1,962), jointly spanning an age
54 range of 30 to 89 years. PFAS were measured with the Metabolon HD4 platform, and lipoprotein and metabolite
55 profiles were measured using Nightingale's nuclear magnetic resonance-spectroscopy platform, and mainly
56 comprised lipoprotein markers. Using linear regression analyses, we quantified age-, sex- and education-
57 adjusted associations of PFOA, PFOS, and PFHxS with clinical lipid measurements and 224 lipoproteins and
58 metabolites.

59 Higher levels of PFAS, particularly PFOS and PFHxS, were associated with higher concentrations of total lipid,
60 cholesterol and phospholipid content in most HDL, IDL, LDL and VLDL subclasses. The effect sizes were age-
61 dependent for the majority of the associations, with the deleterious effects of PFAS being generally stronger in
62 people below compared to those above median age. Our observation that in the general population even low
63 PFAS concentrations are associated with an unfavorable lipid profile, calls for further critical regulation of
64 PFAS substances.

65 ***1. Introduction***

66 Per- and polyfluoroalkyl substances (PFAS) are man-made chemicals that have been widely used in many
67 industrial processes and products since the 1950s (Roth et al. 2021). These chemicals are persistent and resilient
68 in nature, allowing them to circulate in water sources and become widespread around the globe, making them
69 colloquially known as the ‘forever chemicals’ (RIVM ; Nordby, Luck 1956; Stockholm Convention on
70 Persistent Organic Pollutants (POPs) 2001; Buck et al. 2011; Priestly 2018; Sunderland et al. 2019; Grandjean et
71 al. 2020; Schrenk et al. 2020). High environmental PFAS levels may be caused by contamination in the vicinity
72 of PFAS-producing factories, but also by the use and breakdown of PFAS-containing products—such as fire
73 extinguishers, non-stick cooking pans, certain food packaging, textiles, clothing, cosmetics, and pesticides
74 (Sunderland et al. 2019; Barhoumi et al. 2022). Human exposure can occur through contact with a contaminated
75 environment (e.g. through dermal exposure or inhalation), contact with PFAS-containing products, as well as
76 ingestion with drinking water and food (Sunderland et al. 2019). Given the persistence of PFAS, human
77 exposure is ubiquitous and chronic. PFAS accumulate in the human body over time as they are broken down
78 slowly, where the half-life of common PFAS is estimated to be between 4 and 8.5 years (Olsen et al. 2007).

79 Ever since the introduction of PFAS production, health concerns were raised (Nordby, Luck 1956; 3M
80 Company Chemical Division 1963; Sherman 1973; Sunderland et al. 2019). The main focus has long been on
81 direct exposure to high levels of PFAS, which was found to be associated with a range of adverse health
82 outcomes, including obesity, kidney disease, cancer, thyroid disease, hypercholesteremia, dyslipidemia, liver
83 damage, reduced antibody response to vaccination, and a higher risk of severe course of COVID-19 (Stockholm
84 Convention on Persistent Organic Pollutants (POPs) 2001; Priestly 2018; Grandjean et al. 2020; Schrenk et al.
85 2020). Animal studies and studies in high-risk groups, such as children, who are at high risk of adverse effects,
86 and high exposure groups, such as factory workers, have found PFAS to be related with changes in the immune
87 system, proteome, hormones, and metabolome (Liu et al. 2022; Shih et al. 2022). However, evidence of the
88 effects of PFAS in humans remains limited and more research about the presence and the effects of low
89 exposure in the general population is warranted (Sunderland et al. 2019; European Food Safety Authority 2020).

90 The health concerns from PFAS exposure resulted in the classification of certain PFAS as persistent pollutants
91 that require regulation. Specifically, the use of perfluorooctane sulfonic acid (PFOS) and perfluorooctanoic acid
92 (PFOA) has been subjected to growing restrictions (Stockholm Convention on Persistent Organic Pollutants
93 (POPs) 2001; Stockholm Convention on Persistent Organic Pollutants (POPs) 2017). However, despite the
94 increasing scrutiny, many PFAS species remain unregulated and even PFOA and PFOS are not yet fully banned
95 in the European Union (RIVM 2022a). Thus, and worsened by their long half-life, PFAS exposure remains a
96 public health issue (Duffek et al. 2020; Schrenk et al. 2020; RIVM 2021).

97 Specific mechanisms through which PFAS exert their effects remain largely unclear. Previous studies have
98 shown that PFAS are most consistently associated with changes in lipid metabolism, particularly higher
99 cholesterol levels (Priestly 2018). Recent advances in high throughput metabolomic approaches allow the
100 analysis of large lipoprotein and metabolite panels and enable more in-depth examinations of lipid species and
101 lipoprotein subclasses. Indeed, a recent study investigated the effect of PFAS on an extensive lipid panel in a
102 sample of 50-year old adults (Haug et al. 2023). We aim to corroborate and expand upon that work by including
103 a larger group and a wider age range. Especially, we aim to evaluate PFAS exposure levels in the general

104 population and investigate their association with metabolites and lipoproteins, using clinical lipid measurements
105 and targeted metabolomics. To enhance generalizability and robustness of the results, we used two different
106 study populations: the Netherlands Epidemiology of Obesity study (NEO) (n = 584) and the Rhineland Study (n
107 = 1,962).

108

109 **2. Methods**

110 **2.1. Study Populations**

111 *2.1.1. Netherlands Epidemiology of Obesity Study*

112 NEO is a population-based, prospective cohort study of individuals aged 45–65 years, with an oversampling of
113 individuals who are overweight or have obesity. Men and women aged between 45 and 65 years with a self-
114 reported body mass index (BMI) of 27 kg/m² or higher, living in the greater area of Leiden (in the West of the
115 Netherlands) were eligible to participate in the NEO study. In addition, all inhabitants aged between 45 and 65
116 years from one municipality (Leiderdorp) were invited, irrespective of their BMI. Recruitment of participants
117 started in September 2008 and was completed at the end of September 2012. In total, 6,671 participants have
118 been included. Participants were invited to come to the NEO study center of the LUMC for one baseline study
119 visit, where a blood sample of 108 mL was taken from the participants after an overnight fast of at least 10
120 hours (de Mutsert et al. 2013). In the current study, the samples of a random subset of 599 participants from the
121 Leiderdorp sub-population (n=1,671) were used to measure untargeted metabolomic data. Among these
122 individuals, 4 did not have the study outcome (targeted metabolomics) data, 2 were excluded due to missing
123 data on educational level, and 9 were excluded due to measurement errors, leading to a final sample size of n =
124 584 (**Figure 1**).

125 *2.1.2. Rhineland Study*

126 The Rhineland Study is an ongoing community-based cohort study located in two geographically defined areas
127 in Bonn, Germany. Participation is possible by invitation only. To be able to participate, participants had to be
128 above 30 years of age at baseline and have sufficient command of the German language to provide written
129 informed consent. Nightingale measurements were performed in plasma from the first 2,000 consecutive
130 participants, 1,982 of which passed quality control. We further excluded 20 participants due to missing data on
131 educational level, leaving a sample size of n=1,962 to be included in the analyses (**Figure 1**). Of these, 1,805
132 participants had complete data on LDL, HDL, total triglyceride, and cholesterol levels, which were used for the
133 analysis of clinical lipid measurements.

134 **2.2. PFAS measurements**

135 Blood PFAS concentrations were measured using the untargeted Metabolon™ Discovery HD4 platform at
136 Metabolon Inc. (Durham, North Carolina, USA). In brief, this process involves four independent ultra-high-
137 performance liquid chromatography mass spectrometry (UHPLC-MS/MS) platforms (Evans et al. 2014; Rhee et
138 al. 2019). It uses two positive ionization reverse phase chromatography, one negative ionization reverse phase
139 chromatography, and one hydrophilic interaction liquid chromatography negative ionization (Rhee et al. 2019).
140 In NEO, PFOA and PFOS levels were quantified from fasting state serum samples, while in the Rhineland
141 Study PFOA, PFOS and perfluorohexanesulfonic acid (PFHxS) concentrations were obtained from fasting
142 plasma samples. PFAS were quantified as relative concentrations using the mass and charge peaks of the
143 molecules. PFHxS was not measured in NEO, because it was not detectable in serum samples after the
144 necessary sample preparations. To ensure comparability across studies, we Z-standardized all PFAS levels
145 before subsequent analyses. The distribution of PFAS levels in the different studies can be found in
146 Supplementary Figure 1.

147 **2.3. Metabolic and lipoprotein measurements**

148 Clinical lipids, i.e. total serum levels of LDL, HDL and total cholesterol, and triglycerides, were measured in
149 NEO as described previously (de Mutsert et al. 2013). In the Rhineland Study, serum levels of LDL, HDL and
150 total cholesterol, and triglycerides, were measured using routine methods at the University Hospital in Bonn.

151 Fasting serum (NEO) and plasma (Rhineland Study) metabolite levels were quantified using the Nightingale
152 nuclear magnetic resonance untargeted metabolomic platform (Nightingale Health Ltd, Helsinki, Finland),
153 which quantifies 224 metabolites and metabolite ratios. The platform predominantly provides detailed
154 lipoprotein lipid information, in addition to absolute concentrations of various other metabolites, including
155 amino acids, free fatty acids and ketone bodies (Soininen et al. 2015).

156 **2.4. Assessment of covariates**

157 In both the Rhineland Study and NEO, questionnaire and food frequency questionnaires were used to collect
158 demographic and lifestyle information, including current smoking status (yes/no), alcohol intake (g/day), and
159 education (low/middle/high). In the Rhineland Study, missing values (n= 163) for smoking were imputed based
160 on HD4-measured cotinine levels in the blood according to the method described by St Helen et al. (St Helen et
161 al. 2012). To assure the quality of the data, alcohol values belonging to participants reporting an overall
162 improbable caloric intake (<600 or >8,000) were excluded, as per the method of Galbete et al. (Galbete et al.
163 2018). The name, dosage, anatomical therapeutic chemical (ATC) code and prescription status of each
164 medication that participants were currently taking, or had taken in the past year, were recorded in an interview.
165 Use of lipid-lowering medication was based on ATC code C10 in the Rhineland Study and ATC codes C10AA or
166 C10BA in NEO.

167 The International Standard Classification of Education 2011 (ISCED) (UNESCO Institute for Statistics 2012)
168 was used to standardize education across both studies. Participants' education level was reclassified as low
169 (lower secondary education or below), middle (upper secondary education to undergraduate university level) or
170 high (postgraduate university study) in both studies.

171 **2.5. Statistical Analysis**

172 *2.5.1. Imputation of Missing Metabolite Values*

173 A total of 224 metabolites were measured on the targeted metabolomics Nightingale platform. These
174 metabolites had missing values ranging from 0.3% to 9%. Missing values were set to 0 where the levels were
175 considered to be below detection. Missingness due to other reasons (according to the flagging of missing status
176 by Nightingale, e.g. as 'equipment failure') was imputed using a previously described pipeline (Faquih et al.
177 2020). Accordingly, imputed datasets were generated using multiple imputation. To ensure normality, all
178 metabolites were log-transformed after adding 1 to account for 0s.

179 *2.5.2. Linear Regression Models*

180 Multiple linear regression models were used to associate the log-transformed and Z-standardized PFAS
181 concentrations (exposures) with the log-transformed Nightingale and clinical lipid measurements (outcomes). In
182 our first models, we adjusted for biological sex (women/men), age (years) and education (low/middle/high). As
183 PFAS accumulate during the lifespan (Pérez et al. 2013) and may have different effects across age groups, we
184 next included a multiplicative interaction term between age and the PFAS substances. We also assessed possible

185 effect differences between men and women (Koskela et al. 2022) by additionally including a sex-interaction
186 term to our models. If the interaction estimate was significant, we performed a stratified analysis on the basis of
187 sex or the median age (54 years). For ease of comparability in the figures, analyses were run on the Z-
188 standardized metabolite levels after the log transformation. To test whether the associations were dependent on
189 traditional risk behaviors and medication use, we ran additional analyses adjusting for alcohol intake, smoking,
190 BMI and lipid-lowering medication. Moreover, we assessed the robustness of our results by performing a
191 sensitivity analysis where we truncated extreme outlier values (>5 standard deviations (SDs)) in the PFAS
192 levels.

193 *2.5.3. Multiple testing correction*

194 As the Nightingale measurements are inherently highly correlated, we used the method described by Li and Ji
195 (Li, Ji 2005) to calculate the effective number of independent variables. Accordingly, the number of
196 independent Nightingale variables was estimated at 66. We furthermore included 4 clinical lipid measurements
197 as outcomes. Thus, we considered a p-value < 0.0007 (0.05/70) as statistically significant.

198 All analyses were performed using R (R Core Team 2019) v4.1.0 (2021-05-18) in NEO and v4.0.5 (2021-03-31)
199 in the Rhineland Study. Figures were created using the *ggplot2* (Hadley 2016) R package.

200

201 **3. Results**

202 **3.1. Population characteristics**

203 Participants in the Rhineland Study (57% women) had a median age of 54 years (range: 30 – 89), an average
204 BMI of 25.8 (SD: 4.5), and a relatively high education level (**Table 1**). NEO participants (52.6% women) had a
205 median age of 54 years (range: 45 – 66), an average BMI of 25.9 (SD: 4.0), and were mostly of a medium
206 education level. Average alcohol consumption in the Rhineland Study was higher than in the NEO study.
207 Current smokers made up 13.7% of the Rhineland Study and 11.3% of NEO. PFOA and PFOS were measurable
208 in all 599 NEO participants. In the Rhineland Study, PFOA, PFOS, and PFHxS were below the level of
209 detection in none, 17, and three out of 1,962 participants, respectively.

210 **3.2. PFAS and clinical lipids**

211 In the overall analyses, no associations were found between PFOA, PFOS or PFHxS and the clinical lipid
212 measurements when adjusting for age, sex and education (**Table 2**). While this did not differ between men and
213 women, we found statistically significant age-interaction effects for some of the associations (Rhineland Study:
214 PFOS and PFHxS with total cholesterol, PFOA and PFOS with LDL-C; NEO: PFOS with total cholesterol and
215 LDL-C). In the subsequent age-stratified analyses (≤ 54 years; >54 years) we only found an association of PFOS
216 with higher cholesterol levels in the younger age group in NEO (**Supplementary Table 1, Supplementary**
217 **Table 2**).

218 **3.3. PFAS and metabolic profiles**

219 Overall, all PFAS substances were usually, albeit largely non-significantly, associated with higher levels of
220 different cholesterol, fatty acids and the lipid content of differently-sized IDL, LDL and VLDL subclasses after
221 adjustment for sex, age and education. Statistically significant associations were observed between PFOA and a
222 higher concentration and lipid content of small HDL particles in NEO and between PFOA and sphingomyelins,
223 cholesterol in HDL3, and albumin in the Rhineland Study. PFOS was statistically significantly associated with
224 higher fatty acid levels in NEO, while PFHxS was statistically significantly associated with higher levels of
225 cholesterol, fatty acids, albumin, and apolipoprotein A1 (apoA1), and with lower levels of the amino acid
226 phenylalanine in the Rhineland Study (**Figure 2**).

227 We found significant age-interactions for PFOA (NEO: 5; Rhineland Study: 1) and PFHxS (Rhineland Study:
228 $n= 8$), and many for PFOS (NEO: 54; Rhineland Study: 80) in both studies. These age-effects were observed for
229 almost all lipoprotein and metabolite classes, including cholesterol, cholesterol ester and total lipid content of
230 IDLs, LDLs, and VLDLs, as well as apolipoprotein B (apoB), fatty acids, amino acids, albumin, and
231 sphingomyelin levels. The associations were almost always stronger in the younger compared to the older age
232 group (**Figure 3**).

233 Lastly, we checked whether the above-mentioned associations were confounded by smoking, alcohol
234 consumption, BMI, and lipid-lowering medication (**Supplementary Table 1, Supplementary Table 2**). In
235 NEO, the associations remained largely unchanged. In the Rhineland Study, the number of significant
236 associations changed across all PFAS substances. However, while additional adjustment decreased the strength

237 of the effect, particularly when including BMI or alcohol intake, the previously described patterns remained
238 largely the same.

239 Truncating outliers of PFAS levels did not substantially change the results in NEO, but slightly increased the
240 number of significant associations in the Rhineland Study (**Supplementary Table 1, Supplementary Table 2**),
241 indicating that the observed associations were not driven by outliers.

242

243

244 **4. Discussion**

245 **4.1. Summary**

246 In this study, we investigated the association of three PFAS substances with clinically measured lipid
247 biomarkers and a wide range of metabolites (n= 224) in the general population. By combining findings from the
248 NEO Study (n= 584) and the Rhineland Study (n= 1,962), we report common and clinically relevant effects of
249 PFAS on measures of lipid metabolism. Specifically, PFOS and PFHxS were associated with an adverse
250 metabolomic profile characterized by increased levels of apoB, phosphoglycerides, total lipids, fatty acids, and
251 the lipid content of LDL, IDL, and VLDL particles. The effect estimates were consistent with regard to both
252 direction and magnitude in both cohorts and were not driven by outliers, further supporting the validity of our
253 findings. Thus, we interpret our data to indicate that even low PFAS levels in the general population can have a
254 detrimental effect on lipid metabolism.

255 **4.2. Widespread PFAS exposure in the Netherlands and Germany**

256 PFAS exposure is widespread in both Germany (Brede et al. 2010; Duffek et al. 2020; German Environment
257 Agency 2020; Kotthoff et al. 2020) and the Netherlands (Gebbink, van Leeuwen 2020; RIVM 2021; van der Aa
258 2021; RIVM 2022b). Despite the slow phasing out of the production of PFAS substance in the Netherlands
259 (Municipality of Dordrecht 2022), both surface and ground water, soil, vegetation, fish, and stock animals in the
260 area remain highly contaminated. In addition, contamination in surface and drinking water was detected across
261 the western regions of the Netherlands (Gebbink, van Leeuwen 2020). Recently, the National Institute for the
262 Public Health and the Environment (RIVM) concluded that the levels of PFAS in the Netherlands are highly
263 concerning and require further research (RIVM 2021). PFAS exposure is also a problem in Germany, where
264 areas along the Rhine among others are marked as high exposure locations (Brendel et al. 2018; Kotthoff et al.
265 2020). Importantly, PFAS levels are detectable in the groundwater of most and soil samples of all states
266 (German Environment Agency 2020). Indeed, in line with the high contamination levels of both countries and
267 the long half-life of PFAS in human serum of between 4 and 8.5 years (Olsen et al. 2007; Schrenk et al. 2020),
268 we found that PFAS levels were detectable in the blood of nearly all included participants from NEO and the
269 Rhineland Study.

270 **4.3. PFAS levels associated with metabolomic profiles of increased risk of cardiovascular disease**

271 We found that even low PFAS levels were associated with a distinctive lipid profile, characterized by higher
272 cholesterol and lipid content in HDL, IDL, LDL, and VLDL subclasses. We also found associations between
273 PFAS levels and apoB, fatty acids, phosphoglycerides, IDL, and phospholipids, which is largely in line with a
274 recent, smaller study among 50-year-old individuals in Sweden (Haug et al. 2023). A higher lipid content of
275 lipoproteins has been implicated in cardiovascular disease (CVD) (Xiao et al. 2016), while higher levels of fatty
276 acids and apoB have been consistently associated with myocardial infarction (Julkunen et al. 2022). Other
277 studies have linked a similar metabolomic profile to a higher risk of cardiometabolic diseases such as CVD
278 (Tikkanen et al. 2021), hypertension (Palmu et al. 2022), type 2 diabetes (Ahola-Olli et al. 2019), and non-
279 alcoholic fatty liver disease (Sliz et al. 2018). Therefore, our results suggest that PFAS exposure may increase
280 the risk of cardiometabolic outcomes by impacting the lipoprotein profile. Of note, we found that PFHxS, one of
281 the often-used more recent substitutes of PFOA and PFOS (Sunderland et al. 2019; Li et al. 2020), affected
282 metabolite concentrations as well as lipoprotein composition and concentrations in the same way as PFOA and

283 PFOS. Additional adjustment for certain risk behaviors (alcohol consumption, smoking), obesity and lipid-
284 lowering medication, generally decreased the strength of and number of significant associations, but did not
285 substantially change the overall patterns. Thus, the risks associated with PFAS are largely independent of these
286 other factors.

287 **4.4. Effects of PFAS are partially dependent on age**

288 Our population studies jointly covered a wide age-range (30-89 years), which allowed us to investigate whether
289 the effects of PFAS levels in adults differed across age. We found significant age-interactions for most of the
290 PFOA and PFOS associations with lipoproteins, with the effects generally being larger in younger individuals.
291 On the other hand, the associations of PFHxS with metabolite outcomes were less dependent on age. It is
292 unclear what underlies the stronger effects of PFOA and PFOS in younger people. A possible explanation could
293 be the presence of more competing causes in older people, including changes in cholesterol and other lipid
294 levels later in life due to medication use, change in body composition, hormones or diet (Ettinger et al. 1992;
295 Ferrara et al. 1997; Downer et al. 2014; Zhang et al. 2020). Alternatively, it is possible that the timing and
296 duration of a person's exposure impact the effect. For example, early life exposure reportedly has more severe
297 consequences than late-life exposure (Canova et al. 2021). Finally, it may be that the intensity of exposure,
298 rather than cumulative exposure, is an important determinant of the physiological impact of PFAS exposure.
299 Due to the long half-life, the same blood exposure level may result from lower exposures over a longer time
300 period in older compared to younger persons. This might also explain why no clear age-effects were seen for
301 PFHxS: as that has been in use much shorter, blood levels may reflect more similar exposure patterns between
302 younger and older persons.

303 **4.5. Strengths and limitations**

304 Our main limitation stems from the cross-sectional nature of our data. As such, we cannot establish a causal link
305 between the PFAS exposures and the metabolites. Nonetheless, reverse causation is unlikely due to the nature of
306 the associations, as it is highly unlikely that lipoprotein concentrations would affect PFAS levels. Other
307 limitations include the use of different sample media for the measurement of PFAS and Nightingale metabolites
308 in NEO versus the Rhineland Study, as well as the use of relative, rather than absolute, PFAS levels. A strength
309 of our study is that we comprehensively evaluated the effect of PFAS exposure in relation to a detailed lipid
310 profile and a large variety of metabolites across a wide age-range, which has not been assessed before.
311 Moreover, we found consistent and robust associations of PFAS levels with a cardio-metabolic risk profile
312 across two independent European studies, which supports the reliability of our findings. Moreover, our results
313 are in line with findings from a smaller, recent study (Haug et al. 2023), which further corroborates the validity
314 of our results.

315 **4.6. Conclusion**

316 In conclusion, we found that even low levels of PFAS are associated with a detrimental lipid profile in the
317 general population. We report associations between PFAS and higher apoB and lipid content, particularly
318 cholesterol content, of most subclasses of IDL, LDL, and VLDL. Our results corroborate and expand on
319 previous findings by showing a clear link between PFAS levels and an adverse lipid profile across different
320 study populations, even at low PFAS levels. In the Netherlands, pre-determined cut-offs for safe levels of PFAS

321 were recently used to conclude that the PFAS levels in the Westerschelde were no cause for concern (RIVM
322 2022b). However, our results indicate that there may be no safe levels below which exposure is without health
323 hazard. Moreover, we found that a more recently developed PFAS, PFHxS, was as detrimental for health as
324 were older PFAS (PFOA and PFOS). Thus, stricter regulations may be required for all PFAS substances.
325 Furthermore, due to the persistent nature of PFAS and their recirculation in the environment, there is a need to
326 actively remove these chemicals from the environment—methods for which are under development (Trang et al.
327 2022). The combination of the well-documented persistence of PFAS and their harmful effects ensures that
328 exposure to these substances is an enduring public health concern, unless and until we find ways to effectively
329 eliminate PFAS from our environment.

330

331 **References**

- 332 3M Company Chemical Division (1963). 3m brand fluorochemical surfactants. 46.
- 333 Ahola-Olli A. V., Mustelin L., Kalimeri M., Kettunen J., Jokelainen J., Auvinen J., Puukka K.,
334 Havulinna A. S., Lehtimäki T., Kähönen M. J. D. (2019). Circulating metabolites and the risk of type
335 2 diabetes: A prospective study of 11,896 young adults from four finnish cohorts. 62 (12): 2298-
336 2309.
- 337 Barhoumi B., Sander S. G., Tolosa I. (2022). A review on per- and polyfluorinated alkyl substances
338 (pfass) in microplastic and food-contact materials. Environmental Research. 206: 112595.
- 339 Brede E., Wilhelm M., Göen T., Müller J., Rauchfuss K., Kraft M., Hölzer J. (2010). Two-year
340 follow-up biomonitoring pilot study of residents' and controls' pfc plasma levels after pfoa reduction
341 in public water system in arnsberg, germany. International Journal of Hygiene and Environmental
342 Health. 213 (3): 217-223.
- 343 Brendel S., Fetter É., Staude C., Vierke L., Biegel-Engler A. (2018). Short-chain perfluoroalkyl acids:
344 Environmental concerns and a regulatory strategy under reach. Environmental Sciences Europe. 30
345 (1): 9.
- 346 Buck R. C., Franklin J., Berger U., Conder J. M., Cousins I. T., de Voogt P., Jensen A. A., Kannan K.,
347 Mabury S. A., van Leeuwen S. P. (2011). Perfluoroalkyl and polyfluoroalkyl substances in the
348 environment: Terminology, classification, and origins. 7 (4): 513-541.
- 349 Canova C., Di Nisio A., Barbieri G., Russo F., Fletcher T., Batzella E., Dalla Zuanna T., Pitter G.
350 (2021). Pfas concentrations and cardiometabolic traits in highly exposed children and adolescents. Int
351 J Environ Res Public Health. 18 (24)
- 352 de Mutsert R., den Heijer M., Rabelink T. J., Smit J. W., Romijn J. A., Jukema J. W., de Roos A.,
353 Cobbaert C. M., Kloppenburg M., le Cessie S., Middeldorp S., Rosendaal F. R. (2013). The
354 netherlands epidemiology of obesity (neo) study: Study design and data collection. Eur J Epidemiol.
355 28 (6): 513-523.
- 356 Downer B., Estus S., Katsumata Y., Fardo D. W. (2014). Longitudinal trajectories of cholesterol from
357 midlife through late life according to apolipoprotein e allele status. Int J Environ Res Public Health.
358 11 (10): 10663-10693.
- 359 Duffek A., Conrad A., Kolossa-Gehring M., Lange R., Rucic E., Schulte C., Wellmitz J. (2020). Per-
360 and polyfluoroalkyl substances in blood plasma – results of the german environmental survey for
361 children and adolescents 2014–2017 (geres v). International Journal of Hygiene and Environmental
362 Health. 228: 113549.
- 363 Ettinger W. H., Wahl P. W., Kuller L. H., Bush T. L., Tracy R. P., Manolio T. A., Borhani N. O.,
364 Wong N. D., O'Leary D. H. (1992). Lipoprotein lipids in older people. Results from the
365 cardiovascular health study. The chs collaborative research group. Circulation. 86 (3): 858-869.

366 European Food Safety Authority (2020). Outcome of a public consultation on the draft risk
367 assessment of perfluoroalkyl substances in food. 17 (9): 1931E.

368 Evans A., Bridgewater B., Liu Q., Mitchell M., Robinson R., Dai H., Stewart S., DeHaven C., Miller
369 L. J. M. (2014). High resolution mass spectrometry improves data quantity and quality as compared to
370 unit mass resolution mass spectrometry in high-throughput profiling metabolomics. 4 (2): 1.

371 Faquih T., van Smeden M., Luo J., le Cessie S., Kastenmüller G., Krumsiek J., Noordam R., van
372 Heemst D., Rosendaal F. R., van Hylckama Vlieg A., Willems van Dijk K., Mook-Kanamori D. O.
373 (2020). A workflow for missing values imputation of untargeted metabolomics data. *Metabolites*. 10
374 (12)

375 Ferrara A., Barrett-Connor E., Shan J. (1997). Total, ldl, and hdl cholesterol decrease with age in
376 older men and women. The rancho bernardo study 1984-1994. *Circulation*. 96 (1): 37-43.

377 Galbete C., Kröger J., Jannasch F., Iqbal K., Schwingshackl L., Schwedhelm C., Weikert C., Boeing
378 H., Schulze M. B. (2018). Nordic diet, mediterranean diet, and the risk of chronic diseases: The epic-
379 potsdam study. *BMC Medicine*. 16 (1): 99.

380 Gebbink W. A., van Leeuwen S. P. J. (2020). Environmental contamination and human exposure to
381 pfas near a fluorochemical production plant: Review of historic and current pfoa and genx
382 contamination in the netherlands. *Environment International*. 137: 105583.

383 German Environment Agency (2020). Pfas. Came to stay. German Environment Agency. 1-2020: 48.

384 Grandjean P., Timmermann C. A. G., Kruse M., Nielsen F., Vinholt P. J., Boding L., Heilmann C.,
385 Mølbak K. (2020). Severity of covid-19 at elevated exposure to perfluorinated alkylates. *PLOS ONE*.
386 15 (12): e0244815.

387 Hadley W. (2016). *Ggplot2: Elegant graphics for data analysis*.

388 Haug M., Dunder L., Lind P. M., Lind L., Salihovic S. (2023). Associations of perfluoroalkyl
389 substances (pfas) with lipid and lipoprotein profiles. *Journal of Exposure Science & Environmental*
390 *Epidemiology*.

391 Julkunen H., Cichońska A., Tiainen M., Koskela H., Nybo K., Mäkelä V., Nokso-Koivisto J.,
392 Kristiansson K., Perola M., Salomaa V., Jousilahti P., Lundqvist A., Kangas A. J., Soininen P., Barrett
393 J. C., Würtz P. (2022). Atlas of plasma nuclear magnetic resonance biomarkers for health and disease
394 in 118,461 individuals from the uk biobank. 2022.2006.2013.22276332.

395 Koskela A., Ducatman A., Schousboe J. T., Nahhas R. W., Khalil N. (2022). Perfluoroalkyl
396 substances and abdominal aortic calcification. *J Occup Environ Med*. 64 (4): 287-294.

397 Kotthoff M., Fliedner A., Rüdell H., Göckener B., Bücking M., Biegel-Engler A., Koschorreck J.
398 (2020). Per- and polyfluoroalkyl substances in the german environment – levels and patterns in
399 different matrices. *Science of The Total Environment*. 740: 140116.

400 Li J., Ji L. (2005). Adjusting multiple testing in multilocus analyses using the eigenvalues of a
401 correlation matrix. *Heredity (Edinb)*. 95 (3): 221-227.

- 402 Li J., He J., Niu Z., Zhang Y. (2020). Legacy per- and polyfluoroalkyl substances (pfass) and
403 alternatives (short-chain analogues, f-53b, genx and fc-98) in residential soils of china: Present
404 implications of replacing legacy pfass. *Environment International*. 135: 105419.
- 405 Liu H., Sun W., Zhou Y., Griffin N., Faulkner S., Wang L. (2022). Itraq-based quantitative
406 proteomics analysis of sprague-dawley rats liver reveals perfluorooctanoic acid-induced lipid
407 metabolism and urea cycle dysfunction. *Toxicol Lett*. 357: 20-32.
- 408 Municipality of Dordrecht. (2022) Dossier chemours en dupont (pfoa/c8, genx): Gezondheid.
409 https://cms.dordrecht.nl/Inwoners/Overzicht_Inwoners/Dossier_Chemours_en_DuPont/Gezondheid.
410 26/05/2022
- 411 Nordby G. L., Luck J. M. (1956). Perfluorooctanoic acid interactions with human serum albumin. *J*
412 *Biol Chem*. 219 (1): 399-404.
- 413 Olsen G. W., Burris J. M., Ehresman D. J., Froehlich J. W., Seacat A. M., Butenhoff J. L., Zobel L. R.
414 (2007). Half-life of serum elimination of perfluorooctanesulfonate, perfluorohexanesulfonate, and
415 perfluorooctanoate in retired fluorochemical production workers. *Environ Health Perspect*. 115 (9):
416 1298-1305.
- 417 Palmu J., Tikkanen E., Havulinna A. S., Vartiainen E., Lundqvist A., Ruuskanen M. O., Perola M.,
418 Ala-Korpela M., Jousilahti P., Würtz P., Salomaa V., Lahti L., Niiranen T. (2022). Comprehensive
419 biomarker profiling of hypertension in 36□985 finnish individuals. 40 (3): 579-587.
- 420 Pérez F., Nadal M., Navarro-Ortega A., Fàbrega F., Domingo J. L., Barceló D., Farré M. (2013).
421 Accumulation of perfluoroalkyl substances in human tissues. *Environment International*. 59: 354-
422 362.
- 423 Priestly B. (2018). Literature review and report on the potential health effects of perfluoroalkyl
424 compounds, mainly perfluorooctane sulfonate (pfos). Monash University. 44.
- 425 R Core Team (2019). R: A language and environment for statistical computing. Vienna, Austria. URL
426 <https://www.R-project.org/>. R Foundation for Statistical Computing.
- 427 Rhee E. P., Waikar S. S., Rebholz C. M., Zheng Z., Perichon R., Clish C. B., Evans A. M., Avila J.,
428 Denburg M. R., Anderson A. H., Vasan R. S., Feldman H. I., Kimmel P. L., Coresh J. (2019).
429 Variability of two metabolomic platforms in ckd. *Clinical Journal of the American Society of*
430 *Nephrology*. 14 (1): 40.
- 431 RIVM. Pfas. <https://www.rivm.nl/pfas>. 15-9-2021
- 432 RIVM. (2021) Te veel blootstelling aan pfas in nederland. [https://www.rivm.nl/nieuws/te-veel-](https://www.rivm.nl/nieuws/te-veel-blootstelling-aan-pfas-in-nederland)
433 [blootstelling-aan-pfas-in-nederland](https://www.rivm.nl/nieuws/te-veel-blootstelling-aan-pfas-in-nederland). 15-9-2021
- 434 RIVM (2022a). Official start to ban pfas in europe | rivm.
- 435 RIVM (2022b). Pfas in de westerschelde: Eet zo min mogelijk zelf gevangen producten | rivm.
- 436 Roth K., Yang Z., Agarwal M., Liu W., Peng Z., Long Z., Birbeck J., Westrick J., Liu W., Petriello
437 M. C. (2021). Exposure to a mixture of legacy, alternative, and replacement per- and polyfluoroalkyl

438 substances (pfas) results in sex-dependent modulation of cholesterol metabolism and liver injury.
439 Environment International. 157: 106843.

440 Schrenk D., Bignami M., Bodin L., Chipman J. K., Del Mazo J., Grasl Kraupp B., Hogstrand C.,
441 Hoogenboom L., Leblanc J. C., Nebbia C. S., Nielsen E., Ntzani E., Petersen A., Sand S., Vleminckx
442 C., Wallace H., Barregård L., Ceccatelli S., Cravedi J. P., Halldorsson T. I., Haug L. S., Johansson N.,
443 Knutsen H. K., Rose M., Roudot A. C., Van Loveren H., Vollmer G., Mackay K., Riolo F.,
444 Schwerdtle T. (2020). Risk to human health related to the presence of perfluoroalkyl substances in
445 food. EFSA Journal. 18 (9)

446 Sharma M., Loh K. P., Nightingale G., Mohile S. G., Holmes H. M. (2016). Polypharmacy and
447 potentially inappropriate medication use in geriatric oncology. J Geriatr Oncol. 7 (5): 346-353.

448 Sherman H. (1973). Ninety-nine feeding study in rats and dogs with zonyl rp Haskell Laboratory for
449 Toxicology and Industrial Medicine, DUPONT.

450 Shih Y. H., Blomberg A. J., Jørgensen L. H., Weihe P., Grandjean P. (2022). Early-life exposure to
451 perfluoroalkyl substances in relation to serum adipokines in a longitudinal birth cohort. Environ Res.
452 204 (Pt A): 111905.

453 Sliz E., Sebert S., Würtz P., Kangas A. J., Soininen P., Lehtimäki T., Kähönen M., Viikari J.,
454 Männikkö M., Ala-Korpela M., Raitakari O. T., Kettunen J. (2018). Nafld risk alleles in pnpla3,
455 tm6sf2, gckr and lyplal1 show divergent metabolic effects. Human Molecular Genetics. 27 (12):
456 2214-2223.

457 Soininen P., Kangas A. J., Wurtz P., Suna T., Ala-Korpela M. (2015). Quantitative serum nuclear
458 magnetic resonance metabolomics in cardiovascular epidemiology and genetics. Circ Cardiovasc
459 Genet. 8 (1): 192-206.

460 St Helen G., Novalen M., Heitjan D. F., Dempsey D., Jacob P., 3rd, Aziziyeh A., Wing V. C., George
461 T. P., Tyndale R. F., Benowitz N. L. (2012). Reproducibility of the nicotine metabolite ratio in
462 cigarette smokers. Cancer Epidemiol Biomarkers Prev. 21 (7): 1105-1114.

463 Stockholm Convention on Persistent Organic Pollutants (POPs). (2001) The new pops under the
464 stockholm convention.
465 <http://www.pops.int/TheConvention/ThePOPs/TheNewPOPs/tabid/2511/Default.aspx>.

466 Stockholm Convention on Persistent Organic Pollutants (POPs) (2017). The 16 new pops: An
467 introduction to the chemicals added to the stockholm convention as persistent organic pollutants by
468 the conference of the parties.

469 Sunderland E. M., Hu X. C., Dassuncao C., Tokranov A. K., Wagner C. C., Allen J. G. (2019). A
470 review of the pathways of human exposure to poly- and perfluoroalkyl substances (pfass) and present
471 understanding of health effects. Journal of Exposure Science & Environmental Epidemiology.
472 29 (2): 131-147.

473 Tikkanen E., Jägerroos V., Holmes M. V., Sattar N., Ala-Korpela M., Jousilahti P., Lundqvist A.,
474 Perola M., Salomaa V., Würtz P. (2021). Metabolic biomarker discovery for risk of peripheral artery

475 disease compared with coronary artery disease: Lipoprotein and metabolite profiling of 31 657
476 individuals from 5 prospective cohorts. *Journal of the American Heart Association*. 10 (23): e021995.
477 Trang B., Li Y., Xue X.-S., Ateia M., Houk K. N., Dichtel W. R. (2022). Low-temperature
478 mineralization of perfluorocarboxylic acids. 377 (6608): 839-845.
479 UNESCO Institute for Statistics (2012). International standard classification of education isced 2011.
480 Montreal, Quebec H3C 3J7 Canada, UNESCO Institute for Statistics 88.
481 van der Aa M. H., Julia; te Biesebeek, Jan Dirk (2021). Analyse bijdrage drinkwater en voedsel aan
482 blootstelling efsaeuropese voedselveiligheidsautoriteit-4 pfaspoly- en perfluoralkylstoffen in
483 nederland en advies drinkwaterrichtwaarde. Rijksinstituut voor Volksgezondheid en Milieu.
484 Ministerie van Volksgezondheid, Welzijn en Sport.
485 Xiao C., Dash S., Morgantini C., Hegele R. A., Lewis G. F. (2016). Pharmacological targeting of the
486 atherogenic dyslipidemia complex: The next frontier in cvd prevention beyond lowering ldl
487 cholesterol. *Diabetes*. 65 (7): 1767-1778.
488 Zeilmaker M. J. J., P. ; Versteegh, A. ; Pul, A. van ; Vries, W. de ; Bokkers, B. ; Wuijts, S. ; Oomen,
489 A. ; Herremans, J. (2016). Risicoschatting emissie pfoa voor omwonenden. Bilthoven: National
490 Institute for Public Health and the Environment.
491 Zhang P., Su Q., Ye X., Guan P., Chen C., Hang Y., Dong J., Xu Z., Hu W. (2020). Trends in ldl-c
492 and non-hdl-c levels with age. *Aging Dis*. 11 (5): 1046-1057.
493

494 **Statements and Declarations**

495 **Funding**

496 The NEO study is supported by the participating Departments, Division, and Board of Directors of the Leiden
497 University Medical Center, and by the Leiden University, Research Profile Area Vascular and Regenerative
498 Medicine. **D.O. Mook-Kanamori**. is supported by Dutch Science Organization (ZonMW-VENI Grant No.
499 916.14.023). **D. van Heemst**. and **R. Noordam** were supported by a grant of the VELUX Stiftung [grant
500 number 1156]. **T.O. Faquih** was supported by the King Abdullah Scholarship Program and King Faisal
501 Specialist Hospital & Research Center [No. 1012879283]. The Rhineland Study was partly supported by the
502 German Research Foundation (DFG) under Germany's Excellence Strategy (EXC2151-390873048) and
503 SFB1454 - project number 432325352; the Federal Ministry of Education and Research under the Diet-Body-
504 Brain Competence Cluster in Nutrition Research (grant numbers 01EA1410C and FKZ:01EA1809C) and in the
505 framework "PreBeDem - Mit Prävention und Behandlung gegen Demenz" (FKZ: 01KX2230); and the
506 Helmholtz Association under the Initiative and Networking Fund (No. RA-285/19) and the 2023 Innovation
507 Pool.

508 **Competing Interests**

509 **R. Li-Gao** is a part-time clinical research consultant for Metabolon, Inc. All other authors have no relevant
510 financial or non-financial interests to declare.

511 **Author Contributions**

512 **T.O. Faquih**: Conceptualization, Methodology, Formal Analysis, Writing – Original Draft Preparation,
513 Visualization; **E.N. Landstra**.: Conceptualization, Methodology, Formal Analysis, Writing – Original Draft
514 Preparation, Visualization; **A. van Hylckama-Vlieg**: Conceptualization, Supervision, Writing – Reviewing and
515 Editing; **N. A. Aziz**: Conceptualization, Methodology, Writing – Review and Editing; **R. Li-Gao**: Writing –
516 Review and Editing; **R. de Mutsert**: Project Administration, Resources, Funding Acquisition, Writing – Review
517 and Editing; **F.R. Rosendaal**.: Study design, Funding acquisition, Conceptualization; **R. Noordam** and **D. van**
518 **Heemst**: Funding acquisition, Writing – Review and Editing; **D.O. Mook-Kanamori**: Conceptualization,
519 Methodology, Resources, Writing – Reviewing and Editing, Funding Acquisition, Supervision; **K.W. van Dijk**:
520 Conceptualization, Supervision, Writing – Reviewing and Editing; **M.M.B. Breteler**: Conceptualization,
521 Methodology, Resources, Writing – Reviewing and Editing, Data Curation, Funding Acquisition, Supervision.

522

523 All authors read and approved the final manuscript

524

525 **Data availability**

526 Due to the privacy of the participants of the NEO study and legal reasons, we cannot publicly deposit the data.
527 Furthermore, NEO study participants did not sign informed consent to make their data publicly available. Data
528 can be made available upon request to interested qualified researchers. Data requests should be sent to the NEO
529 Executive Board which can be contacted via <https://www.lumc.nl/org/neo-studie/contact/>.

530 Rhineland Study data used for this manuscript are not publicly available due to data protection regulations.

531 Access to data can be provided to scientists in accordance with the Rhineland Study's Data Use and Access

532 Policy. Requests for additional information and/or access to the datasets can be send to RS-DUAC@dzne.de.

533 All authors had full access to their respective study data and take responsibility for the integrity of the data and
534 the accuracy of the analysis.

535

536 **Ethics approval**

537 The NEO study was approved by the medical ethical committee of the Leiden University Medical Centre
538 (LUMC) and all participants gave their written informed consent.

539

540 The ethics committee of the medical faculty of the University of Bonn approved the undertaking of the
541 Rhineland Study and it was carried out according to the recommendations of the International Council for
542 Harmonisation Good Clinical Practice standards.

543


544 **Consent to participate**

545 Written informed consent was acquired from all participants per the Declaration of Helsinki in both the NEO
546 and Rhineland Study.

547 **Tables and Figures**

548 *Figure 1: Overview of study population selection for NEO (A) and the Rhineland Study (B)*

549



550

551

552

553

554

555

556

557 *Table 1: Population characteristics of NEO and the Rhineland Study*

Characteristic [†]	NEO			Rhineland Study		
	All (n= 584)	Women (n= 308)	Men (n= 276)	All (n= 1,962)	Women (n= 1,104)	Men (n= 858)
Age (median years (range))	56 (45 – 66)	56 (45 – 66)	56 (45 – 66)	54 (30 – 95)	54 (30 – 95)	54 (30 – 93)
Sex (Women (%))	308 (52.7)			1104 (56.3)		
PFOA (mean (SD))	1.07 (0.50)	1.06 (0.51)	1.08 (0.49)	1.11 (0.53)	1.10 (0.62)	1.13 (0.46)
PFOS (mean (SD))	1.08 (0.56)	1.09 (0.60)	10.6 (0.53)	1.21 (0.8)	1.05 (0.91)	1.41 (1.71)
PFHxS (mean (SD))				1.09 (0.69)	0.99 (0.61)	1.22 (0.77)
Education (N (%))						
<i>Low</i>	97.0 (16.6)	40 (14.5)	57 (18.5)	46 (2.3)	38 (3.4)	8 (0.9)
<i>Middle</i>	391 (67.0)	173 (62.7)	218 (70.8)	871 (44.4)	542 (49.1)	329 (38.3)
<i>High</i>	96 (16.4)	63 (22.7)	33 (10.7)	1045 (53.3)	524 (47.5)	521 (60.7)
BMI (kg/m ² (SD))	25.9 (4.0)	26.6 (3.5)	25.3 (4.4)	25.8 (4.5)	25.3 (4.7)	26.3 (4.2)
LDL (mmol/L (SD))	3.6 (0.9)	3.6 (0.9)	3.6 (1.0)	3.2 (0.9)	3.2 (0.9)	3.3 (0.,9)
HDL (mmol/L (SD))	1.6 (0.5)	1.3 (0.3)	1.8 (0.4)	1.7 (0.5)	1.9 (0.5)	1.4 (0.4)
Cholesterol (mmol/L (SD))	5.7 (1.1)	5.6 (1.0)	5.9 (1.1)	5.2 (1.0)	5.3 (1.0)	5.1 (1.0)
Triglycerides (mmol/L (SD))	1.2 (0.8)	1.4 (0.9)	1.0 (0.6)	1.3 (0.8)	1.1 (0.6)	1.5 (1.0)
Smoking (N (%))	66 (11.3)	31 (11.2)	35 (11.4)	269 (13.7)	134 (12.1)	135 (15.7)
Alcohol (g/day (SD)) [‡]	14.0 (15.3)	19.0 (18.8)	9.6 (10.1)	19.4 (25.8)	15.4 (20.4)	24.7 (30.7)

Notes

[†] Number of missing values in the Rhineland Study: BMI (n= 13; 0.7%), LDL (n= 157; 8.0%), HDL (n= 157; 8.0%), Cholesterol (n= 157; 8.0%), Triglycerides (n= 157; 8.0%), Smoking (n= 0; 0%), Alcohol (n= 234; 11.9%)

[‡] In the Rhineland Study, alcohol intake of participants reporting an overall improbable caloric intake (<600 or >8,000) were excluded.

Abbreviations: Standard deviation (SD), perfluorooctanoic acid (PFOA), perfluorooctane sulfonic acid (PFOS), perfluorohexanesulfonic acid (PFHxS), body mass index (BMI), low density lipoprotein (LDL), high density lipoprotein (HDL)

559 Table 2: Relation of blood PFAS levels with clinical lipid measurements (log-transformed) in NEO and the Rhineland Study

PFAS	Study	Model [†]	LDL-C		HDL-C		Total cholesterol		Triglycerides	
			β [95%CI]	<i>p</i> -value [‡]	β [95%CI]	<i>p</i> -value [‡]	β [95%CI]	<i>p</i> -value [‡]	β [95%CI]	<i>p</i> -value [‡]
PFOA	NEO	Overall	0.019 [0.001; 0.036]	0.0413	0.016 [0.004; 0.029]	0.0112	0.020 [0.007; 0.034]	0.0025	0.013 [-0.010; 0.036]	0.2787
	Rhineland Study	Overall	0.005 [-0.006; 0.016]	0.388	0.007 [-0.001; 0.016]	0.0690	0.008 [-0.001; 0.016]	0.0665	-0.001 [-0.015; 0.014]	0.9362
PFOS	NEO	Overall	0.023 [0.004; 0.041]	0,0153	0.007 [-0.006; 0.021]	0.2675	0.020 [0.007; 0.034]	0.0037	0.016 [-0.009; 0.040]	0.2031
	Rhineland Study	Overall	0.007 [-0.003; 0.017]	0.1726	0.005 [-0.002; 0.013]	0.1575	0.007 [-0.001; 0.014]	0.0837	-0.005 [-0.018; 0.008]	0.4502
PFHxS	Rhineland Study	Overall	0.013 [0.003; 0.023]	0.0128	0.012 [0.004; 0.019]	0.0024	0.012 [0.004; 0.020]	0.0023	-0.006 [-0.019; 0.007]	0.3969

Notes

[‡]A *p* value of < 0.0007 was considered significant after accounting for multiple testing using the Li and Ji method

[†] Models were sex-, age- and education-adjusted.

Abbreviations: Beta estimate (β), confidence interval (CI), perfluorooctanoic acid (PFOA), perfluorooctane sulfonic acid (PFOS), perfluorohexanesulfonic acid (PFHxS), low density lipoprotein (LDL), high density lipoprotein (HDL)

561 *Figure 2: Plotted beta estimates and their distribution per metabolite class for NEO and the Rhineland Study for*
 562 *PFOA (A), PFOS (B), and PFHxS (C), where the top 5 significant hits are annotated*

563 PFOA

564

565

566

567

568

569


570

571


572

573


574




575 PFOS



576 PFHXS



577 *Figure 3: Beta/beta plots showing the beta estimates in the young (≤ 54 years) versus old (> 54 years) group*
578 *where the age interaction term was significant for NEO (A, B) and the Rhineland Study (C, D, E)*



579

580

581

582

583

584



585



586



587

588 **Supplementary Figures**

589 Supplementary Figure 1: Distribution of the PFAS levels in NEO (A) and the Rhineland Study (B), where
590 outliers (>5 standard deviations) are truncated for PFOA (n= 9), PFOS levels (n= 5) and PFHxS (n= 4) in the
591 Rhineland Study.




A**B**



Metabolite group

Metabolite group



Metabolite group

